European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 151, Issue 1 , Pages 86-90 , July 2010

Prevalence of genital human papillomavirus infection and genotypes among women from Fujian province, PR China

  • Dongmei Wu

      Affiliations

    • College of Public Health, Fujian Medical University, Fuzhou City, Fujian Province, China
    • Department of Gynecology and Obstetrics, The Second Peoples Hospital of Fujian Province, Fuzhou City, Fujian Province, China
    • ,
  • Lin Cai

      Affiliations

    • College of Public Health, Fujian Medical University, Fuzhou City, Fujian Province, China
    • Corresponding Author InformationCorresponding author at: No. 88 Jiaotong Road, Fujian Medical University, Fuzhou City, Fujian Province, China. Tel.: +86 0591 83569264; fax: +86 0591 22862510.
    • ,
  • Meng Huang

      Affiliations

    • College of Public Health, Fujian Medical University, Fuzhou City, Fujian Province, China
    • ,
  • Yizhen Zheng

      Affiliations

    • Department of Gynecology and Obstetrics, The Second Peoples Hospital of Fujian Province, Fuzhou City, Fujian Province, China
    • ,
  • Jiang Yu

      Affiliations

    • Department of Gynecology and Obstetrics, The Second Peoples Hospital of Fujian Province, Fuzhou City, Fujian Province, China

Received 22 October 2009 ,Revised 9 February 2010 ,Accepted 17 February 2010.

References 

  1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–350
  2. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. Clin Pathol. 2002;55:244–265
  3. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16:1–17
  4. Cuzick JA, Szarewski H, Cubie G, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871–1876
  5. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327:1272–1278
  6. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7:11–22
  7. Fehrmann F, Laimins LA. Human papillomaviruses targeting differentiating epithelial cells for malignant transformation. Oncogene. 2003;22:5201–5207
  8. Bosch FX, Manos MM, Munoz N, et al. International biology study on cervical cancer (IBSCC) study group. Prevalence of human papillomavirus in cervical cancer: worldwide perspective. J Natl Cancer Inst. 1995;87:796–802
  9. Munoz N, Bosch FX, de Sanjosae S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–527
  10. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009;101(7):475–487
  11. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161–2170
  12. Shefer A, Markowitz L, Deeks S, et al. Early experience with human papillomavirus vaccine introduction in the United States, Canada, and Australia. Vaccine. 2008;26(S10):K68–K75
  13. World Health Organization . Cytological screening in the control of cervical cancer:technical guidelines. Geneva: World Health Organization; 1988;
  14. Kalof AN, Evans MF, Simmons-Arnold L, Beatty BG, Cooper K. p16INK4A immunoexpression and HPV in situ hybridization signal patterns: potential markers of high-grade cervical intraepithelial neoplasia. Am J Surg Pathol. 2005;29:674–679
  15. Wright TC. Cervical cancer screening in the 21st century: is it time to retire the PAP smear?. Clin Obst Gynecol. 2007;50:313–323
  16. Villa L, Denny L. Methods for detection of HPV infection and its clinical utility. Int J Gynecol Obstet. 2006;94:S71–80
  17. Gaëlle AV Boulet, Caroline AJ Horvath, Sarah B, Johannes B. Human papillomavirus in cervical cancer screening: important role as biomarker. Cancer Epidemiol Biomarkers Prev. 2008;17(4):810–817
  18. Markowitz LE, Unger ER, Mona S. Primary and secondary prevention of cervical cancer—opportunities and challenges. J Natl Cancer Inst. 2009;101(7):439–440
  19. Lin H, Ma YY, Moh JS, Ou YC, Shen SY, ChangChien CC. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. Gynecol Oncol. 2006;101(1):40–45
  20. Lin M, Yang LY, Li LJ, Wu JR, Peng YP, Luo ZY. Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province. Aust New Zeal J Obstet Gynaecol. 2008;48:189–194
  21. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88:63–73
  22. Ding DC, Hsu HC, Huang RL, et al. Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan: an indication of viral oncogenic potential. Eur J Obstet Gynecol Reprod Biol. 2008;140(2):245–251

PII: S0301-2115(10)00106-5

doi: 10.1016/j.ejogrb.2010.02.040

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 151, Issue 1 , Pages 86-90 , July 2010

Article Tools

* Image Usage & Resolution